Looks like the next issue of the New England Journal of Medicine will have the Head-to-head with Psilocybin+SSRI vs. SSRI, to be released April 14th at 5 PM.
SSRIs are standard treatment for patients with Major Depressive Disorder (MDD). One of the leaders of this study posted on Twitter last week and is teasing us
https://twitter.com/RCarhartHarris/status/1380049694953512960?s=20
- RCarhartHarris
What's interesting is that the lead for this study is Dr. David Nutt, who also Leads CMPS' advisory board https://clinicaltrials.gov/ct2/show/record/NCT03429075?term=psilocybin&draw=3&rank=22
What's even more interesting is that CMPS was recently granted patents for this exact use case of psilocybin
And finally, it looks like CMPS has scheduled a 'corporate update' the morning after NEJM results will be published i.e. April 15 8 AM ET
Good news on the horizon?
Disclaimer: not a financial advisor, long CMPS stock and April and May calls 40/45/50/60